Literature DB >> 34458056

Tumor-promoting function of PIMREG in glioma by activating the β-catenin pathway.

Dekang Wang1, Aili Hu2, Hao Peng1, Dongbo Li2, Li Zhang1.   

Abstract

Glioma is the most common primary brain tumor in adults with an adverse prognosis and obscure pathogenesis. PICALM interacting mitotic regulator protein (PIMREG) functions as an oncogene in multiple types of cancer, but its function in glioma remains unknown. The Gene Expression Profiling Interactive Analysis 2 (GEPIA2, http://gepia2.cancer-pku.cn/#index) showed that PIMREG expression in the glioma tissues was higher than that in normal brain tissues. Herein, cell counting kit-8 assay and flow cytometry analysis exhibited that overexpression of PIMREG significantly promoted the proliferation of glioma cells and the transition from G1 phase of the cell cycle to S phase. Wound-healing and transwell assays showed that overexpression of PIMREG markedly enhanced the migration and invasion of glioma cells. Western blot analysis revealed that overexpression of PIMREG increased the expression of cyclin D1, cyclin E, Vimentin, matrix metalloproteinase (MMP)-2, and MMP-9, but reduced the expression of E-cadherin. In addition, overexpression of PIMREG activated the β-catenin signaling pathway, as evidenced by the increased total and nuclear expression of β-catenin and the up-regulated expression of its downstream target c-myc. Furthermore, immunofluorescence staining further indicated the increased nuclear translocation of β-catenin in PIMREG-overexpressing cells. However, knockdown of PIMREG exerted opposite effects on glioma cells. Blockade of the β-catenin signaling by ICG-001 markedly impeded the promoting effects of PIMREG on glioma cell proliferation and invasion. In conclusion, PIMREG acts as a tumor promoter in glioma at least partly via activating the β-catenin signaling pathway. This study provides new insights into the molecular mechanism for glioma pathogenesis and treatment. © King Abdulaziz City for Science and Technology 2021.

Entities:  

Keywords:  Cell invasion; Cell proliferation; Glioma; Oncogene; PIMREG; β-Catenin

Year:  2021        PMID: 34458056      PMCID: PMC8302699          DOI: 10.1007/s13205-021-02922-5

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.893


  46 in total

Review 1.  Cyclins and cell cycle checkpoints.

Authors:  D G Johnson; C L Walker
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

2.  The effects of histamine H1 type receptor (H1R) in regulating osteoblastic cell differentiation and mineralization.

Authors:  Yanpeng Sun; Xiaodong Peng; Yanzhou Li; Husheng Ma; Dongfang Li; Xiangqin Shi
Journal:  Artif Cells Nanomed Biotechnol       Date:  2019-12       Impact factor: 5.678

Review 3.  The epidemiology of glioma in adults: a "state of the science" review.

Authors:  Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

Review 4.  Glioma epigenetics: From subclassification to novel treatment options.

Authors:  Olga Gusyatiner; Monika E Hegi
Journal:  Semin Cancer Biol       Date:  2017-11-21       Impact factor: 15.707

5.  Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression.

Authors:  Hong Ma; Cu Nguyen; Kyung-Soon Lee; Michael Kahn
Journal:  Oncogene       Date:  2005-05-19       Impact factor: 9.867

6.  FAM64A positively regulates STAT3 activity to promote Th17 differentiation and colitis-associated carcinogenesis.

Authors:  Zhi-Sheng Xu; Hong-Xia Zhang; Wei-Wei Li; Yong Ran; Tian-Tian Liu; Mei-Guang Xiong; Qing-Lan Li; Su-Yun Wang; Min Wu; Hong-Bing Shu; Huimin Xia; Yan-Yi Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-06       Impact factor: 11.205

7.  MicroRNA-6071 Suppresses Glioblastoma Progression Through the Inhibition of PI3K/AKT/mTOR Pathway by Binding to ULBP2.

Authors:  Yunyan Zhou; Hongwei An; Gang Wu
Journal:  Onco Targets Ther       Date:  2020-09-23       Impact factor: 4.147

8.  The CALM and CALM/AF10 interactor CATS is a marker for proliferation.

Authors:  Leticia Fröhlich Archangelo; Philipp A Greif; Michael Hölzel; Thomas Harasim; Elisabeth Kremmer; Gerhard K H Przemeck; Dirk Eick; Aniruddha Jayant Deshpande; Christian Buske; Martin Hrabé de Angelis; Sara Teresinha Olalla Saad; Stefan K Bohlander
Journal:  Mol Oncol       Date:  2008-09-04       Impact factor: 6.603

Review 9.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

10.  The transcriptional network for mesenchymal transformation of brain tumours.

Authors:  Maria Stella Carro; Wei Keat Lim; Mariano Javier Alvarez; Robert J Bollo; Xudong Zhao; Evan Y Snyder; Erik P Sulman; Sandrine L Anne; Fiona Doetsch; Howard Colman; Anna Lasorella; Ken Aldape; Andrea Califano; Antonio Iavarone
Journal:  Nature       Date:  2009-12-23       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.